At a maintenance dose of 1.2 to 2.3mg, pricing climbs to $399 to $499 or more a month, which can undo the upfront savings for patients who spend most of treatment at maintenance
Here, we emulate a clinical trial that compares outcomes following initiation of GLP1-RA vs Dipeptidyl peptidase-4 inhibitors (DPP4i), as active comparators, in U.S
Clinical evidence supporting the anti-inflammatory effects of GLP-1 receptor agonists comes primarily from cardiovascular outcome trials and mechanistic studies, though most research has examined standard therapeutic doses rather than specifically low-dose regimens
Currently, there are several GLP-1 RA medications delivered by injection, which are sold under various brand names, though availability and licensing vary significantly by country (Table 1)
From monocyte-derived macrophages to resident macrophages-how metabolism leads their way in cancer
Liraglutide attenuates the inflammatory response by inhibiting IKK-/NF-B, thereby reducing islet -cell apoptosis